PTCT - PTC Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.01
-0.30 (-0.83%)
At close: 4:00PM EDT

36.01 -0.00 (-0.00%)
After hours: 5:35PM EDT

Stock chart is not supported by your current browser
Previous Close36.31
Open36.42
Bid36.01 x 900
Ask36.40 x 900
Day's Range34.94 - 36.69
52 Week Range14.56 - 52.95
Volume971,101
Avg. Volume1,286,359
Market Cap1.673B
Beta2.99
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.00
Trade prices are not sourced from all markets
  • How Is PTC Therapeutics Positioned after Q1 2018?
    Market Realist5 hours ago

    How Is PTC Therapeutics Positioned after Q1 2018?

    Should You Be Watching PTC Therapeutics? Wall Street analysts estimate that PTC Therapeutics (PTCT) will generate revenues of $66.1 million in the second quarter, which represents a 37.9% YoY (year-over-year) growth. PTC Therapeutics’ Emflaza, which was launched in May 2017, primarily pushed its revenue growth.

  • Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?
    Market Realist7 hours ago

    Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?

    In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial, which is evaluating the safety profile of risdiplam (RG7916) in babies with type 1 SMA (spinal muscular atrophy).

  • Analysts’ Recommendations for PTC Therapeutics in June
    Market Realist9 hours ago

    Analysts’ Recommendations for PTC Therapeutics in June

    In June, the Committee for Medicinal Products for Human Use (or CHMP) of the European Medicines Agency (or EMA) recommended a positive opinion for the expansion of Translarna’s indication to include ambulatory children between the ages of two and five years with nonsense mutation Duchenne muscular dystrophy. The CHMP recommendation was based on data from the PTC Therapeutics Study 030.

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks13 hours ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Motley Fool13 hours ago

    Big Biotech Stock Pops and Drops This Week

    Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.

  • PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2%
    Zacks2 days ago

    PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2%

    PTC Therapeutics (PTCT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
    Investor's Business Daily2 days ago

    Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs

    PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.

  • TheStreet.com2 days ago

    Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

    Sarepta shares were up $10.23 -- or 7.11% -- to $154.16 in mid-afternoon trading Wednesday after adding 36.8% Tuesday after the firm disclosed impressive test results for its new gene therapy designed to cure a rare form of muscular dystrophy. , which took a 30.6% hit Tuesday on Sarepta's announcement, regained some of its losses and rebounded 6.26% to $35.32 as of Wednesday afternoon. Zhong anticipates Sarepta will continue to rally, as investors are excited about the quality of findings on the gene therapy's effectiveness, as well as about the drug's market potential.

  • Don't Get Too Excited About PTC Therapeutics (Yet)
    Motley Fool3 days ago

    Don't Get Too Excited About PTC Therapeutics (Yet)

    PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.

  • Sarepta's Stock Soars on Encouraging Gene Therapy Results
    Zacks3 days ago

    Sarepta's Stock Soars on Encouraging Gene Therapy Results

    Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.

  • Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
    Motley Fool3 days ago

    Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday

    Welcome to biotech investing.

  • TheStreet.com3 days ago

    Biotech Firm Sarepta Surges 40% on Positive Test Results

    Sarepta Therapeutics Inc. soared nearly 40% in Tuesday trading after publishing impressive results for a new gene therapy designed to treat a rare form of muscular dystrophy. However, the news pushed shares of rival drugmaker PTC Therapeutics Inc.

  • Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
    Market Realist3 days ago

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial

  • PTC Therapeutics' Spinal Muscular Atrophy Study Successful
    Zacks4 days ago

    PTC Therapeutics' Spinal Muscular Atrophy Study Successful

    PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

  • S&P 500’s Top Losses: Why Biogen Declined
    Market Realist4 days ago

    S&P 500’s Top Losses: Why Biogen Declined

    The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen    

  • ACCESSWIRE4 days ago

    Today’s Research Reports on Stocks to Watch: PTC Therapeutics and Catalyst Biosciences

    NEW YORK, NY / ACCESSWIRE / June 19, 2018 / Shares of PTC Therapeutics saw big gains in Monday trading after announcing positive data with its partner Roche on their spinal muscular atrophy drug, risdiplam. Shares of Catalyst Biosciences were plummeting after announcing a worrisome update on its ongoing phase ½ trial investigating its next generation Factor IX (FIX) candidate CB 2679d/ISU304. PTC Therapeutics, Inc. shares closed up 27.51% on about 11.7 million shares traded yesterday.

  • PTC Therapeutics Inc (NASDAQ:PTCT) Is Expected To Breakeven
    Simply Wall St.4 days ago

    PTC Therapeutics Inc (NASDAQ:PTCT) Is Expected To Breakeven

    PTC Therapeutics Inc’s (NASDAQ:PTCT): PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. With the latest financial yearRead More...

  • Why Rent-A-Center, PTC Therapeutics, and Dropbox Jumped Today
    Motley Fool4 days ago

    Why Rent-A-Center, PTC Therapeutics, and Dropbox Jumped Today

    Find out which of these stocks got a buyout bid.

  • Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
    Motley Fool4 days ago

    Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle

    Investors value a new round of data for PTC's spinal muscular atrophy drug.

  • Benzinga4 days ago

    William Blair Upgrades PTC Therapeutics On Risdiplam Prospects

    PTC Therapeutics, Inc. (NASDAQ: PTCT ) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies. The Rating William Blair analyst Raju Prasad ...

  • CNBC4 days ago

    Biogen plunges after rival drug for spinal muscular atrophy shows promise

    Biogen tumbled 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it. Biogen has a few new drugs in the pipeline, including one that could help the company defend its leadership in MS drug therapy, but these are at least two years away reaching the market. Biogen BIIB tumbled as much as 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it.

  • Bloomberg4 days ago

    PTC Therapeutics Up Most Since 2016 on Rare-Disease Drug Results

    PTC Therapeutics Inc. shares rose to their highest price since August 2015 after the company said its experimental drug for spinal muscular atrophy helped the vast majority of babies who got the treatment. Over the weekend the company reported that after 182 days of treatment, 91 percent of babies on the drug improved more than four points on a scale that measures motor milestone developments in patients with a form of spinal muscular atrophy, or SMA. Spinal muscular atrophy is a rare disease that progressively takes away people’s physical strength and their ability to walk, eat and breathe.

  • Reuters5 days ago

    Roche SMA drug shines in study as costly new therapies advance

    A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive. PTC Therapeutics, which struck a licensing deal with Roche in 2011 for its SMA programme, said more than 90 percent of babies with severe Type 1 SMA given the RG7916 drug achieved a greater than four-point increase in a test to measure their neuromuscular progress six months after treatment began. Novartis is also quickly advancing in the SMA field with its $8.7 billion acquisition this year of U.S.-based Avexis that is working on a gene therapy for the disorder.

  • TheStreet.com5 days ago

    PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

    soared in premarket trading on Monday, June 18, after the biotech firm over the weekend presented updated interim clinical data on spinal muscular atrophy (SMA) drug risdiplam. The Chop-Intend is an assessment of motor skill in SMA Type 1. South Plainfield, N.J.-based PTC is collaborating with Roche Holdings AG and the SMA Foundation on the program.

  • Benzinga5 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! JD.Com Inc(ADR) (NASDAQ: JD ) was trading higher by ...